# EDGAR Filing Document

**Accession Number:** 0001873032
**File Stem:** 0001193125-26-051663
**Filing Date:** 2026-2
**Character Count:** 13818
**Document Hash:** 808e3e4456fe6fcf02e721b83071adb9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-051663.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001193125-26-051663

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RAPID MICRO BIOSYSTEMS, INC.
- **CENTRAL INDEX KEY:** 0001380106
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208121647
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92824
- **FILM NUMBER:** 26634099

**BUSINESS ADDRESS:**
- **STREET 1:** 25 HARTWELL AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 978-349-3200

**MAIL ADDRESS:**
- **STREET 1:** 25 HARTWELL AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RAPID MICRO BIOSYSTEMS INC
- **DATE OF NAME CHANGE:** 20061103
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Endeavour Medtech Growth II LP
- **CENTRAL INDEX KEY:** 0001873032

**ORGANIZATION NAME:**
- **EIN:** 981530409
- **STATE OF INCORPORATION:** Y7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** P.O. BOX 656, EAST WING, TRAFALGAR COURT
- **STREET 2:** LES BANQUES
- **CITY:** ST PETER PORT
- **PROVINCE COUNTRY:** Y7
- **BUSINESS PHONE:** 44 1481 749 714

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** P.O. BOX 656, EAST WING, TRAFALGAR COURT
- **STREET 2:** LES BANQUES
- **CITY:** ST PETER PORT
- **PROVINCE COUNTRY:** Y7

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Issuer:** Rapid Micro Biosystems, Inc.

**Title of Class of Securities:** Common Stock, par value $0.01

**CUSIP Number:** 75340L104

**Date of Event Which Requires Filing of this Statement:** 12/31/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Endeavour Medtech Growth II LP | Names of Reporting Persons<br>Endeavour Medtech Growth II LP |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Y7 | Citizenship or Place of Organization<br>Y7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2257099 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2257099 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2257099 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2257099 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.7% | Percent of Class Represented by Amount in Row (9)<br>5.7% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** (1) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP.
(2) Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025 (the "Form 10-Q").

---

| 1. | Names of Reporting Persons<br>Endeavour Medtech Growth II Parallel LP | Names of Reporting Persons<br>Endeavour Medtech Growth II Parallel LP |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Y7 | Citizenship or Place of Organization<br>Y7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2257099 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2257099 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2257099 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2257099 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.7% | Percent of Class Represented by Amount in Row (9)<br>5.7% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** (1) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP.
(2)  Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025.

---

| 1. | Names of Reporting Persons<br>Endeavour Medtech II GP Limited | Names of Reporting Persons<br>Endeavour Medtech II GP Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Y7 | Citizenship or Place of Organization<br>Y7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2257099 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2257099 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2257099 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2257099 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.7% | Percent of Class Represented by Amount in Row (9)<br>5.7% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** (3) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP.
(4)  Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025.

---

**Item 1(a). Name of Issuer:**
Rapid Micro Biosystems, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
25 Hartwell Avenue, Lexington, MA 02421

**Item 2(a). Name of Person Filing:**
This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

 (i) Endeavour Medtech Growth II LP
(ii) Endeavour Medtech Growth II Parallel LP
(iii) Endeavour Medtech II GP Limited

**Item 2(b). Address of Principal Business Office:**
The address of the principal business and principal office of each of the Reporting Persons is P.O. Box 656, East Wing Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3PP

**Item 2(c). Citizenship:**
Each of (1) Endeavour Medtech Growth II LP, (2) Endeavour Medtech Growth II Parallel LP and (3) Endeavour Medtech II GP Limited is a Guernsey limited partnership.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.01

**Item 2(e). CUSIP Number:**
75340L104

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Endeavour Medtech Growth II LP
2,217,190 shares of Class A common stock are held of record by Endeavour Medtech Growth II LP ("EMG II"). Endeavour Medtech II GP Limited ("Endeavour GP") is the general partner of EMG II.
Endeavour Medtech Growth II Parallel LP
39,909 shares of Class A common stock are held of record by Endeavour Medtech Growth II Parallel LP ("EMG II AFF"). Endeavour GP is the general partner of EMG II AFF.
As a result of foregoing, and the relationships described in Item 2(a) of this Schedule 13G, the Reporting Persons may be deemed to share ownership over the reported 2,257,099 shares of Class A common stock, but the filing of this Statement shall not be deemed an admission of such beneficial ownership by any of the Reporting Persons for purposes of Section 13(d) or Section 13(g) or for any other purpose.

**(b) Percent of class:**

5.7%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

0

**(ii) Shared power to vote or to direct the vote:**

2,257,099

**(iii) Sole power to dispose or to direct the disposition of:**

0

**(iv) Shared power to dispose or to direct the disposition of:**

2,257,099

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

—

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Endeavour Medtech Growth II LP**

**Date:** 02/13/2026

**By:** /s/ Nick Barton

**Name & Title:** Nick Barton, Director

**Endeavour Medtech Growth II Parallel LP**

**Date:** 02/13/2026

**By:** /s/ Nick Barton

**Name & Title:** Nick Barton, Director

**Endeavour Medtech II GP Limited**

**Date:** 02/13/2026

**By:** /s/ Nick Barton

**Name & Title:** Nick Barton, Director